Interview: Judith Greciet – CEO, Onxeo, France
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Resulting from the merger of BioAlliance Pharma (France) and Topotarget (Denmark) in July 2014, Onxeo is a new leader in European biotechnology. Thanks to a unique portfolio of advanced stage products and dedicated teams of experts, Onxeo aims to take a leading position in the field of orphan oncology drugs. Through bringing pioneering drugs to market, the company wants to improve patients’ lives, fund continuous investment in R&D of orphan diseases, and create value for all company’s stakeholders and shareholders. It has three strategic programs in advanced development and two products already registered in the European and US markets, demonstrating its teams’ expertise and know-how.
49 boulevard du Général Martial Valin
75015 PARIS, France
Tel: +33 (0)1 45 58 76 00
Fax: +33 (0)1 45 58 08 81
Investors: investors@onxeo.com
Email: contact@onxeo.com
Website: www.onxeo.com
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Iconic French skincare specialist, Pierre Fabre has been enjoying a hot streak of late, with its dermo-cosmetics business registering hefty sales growth of more than EUR 350 (USD 392) million…
Christopher Cuniasse, managing director of Fagron France, sheds light on the specialty area of pharmaceutical compounding and its link with personalized medicine, noting the benefits it can deliver to health…
Éric Ducournau, global CEO of Pierre Fabre Group, the second largest dermo-cosmetic company worldwide and the third-largest French pharmaceutical laboratory, provides insights into the group’s on-going internationalization and its emerging…
Inventiva is a French clinical-stage biotech company focused on developing oral small molecule epigenetic modulators in therapeutic areas with high unmet medical needs such as fibrosis, lysosomal storage disorders and…
Inotrem is a French biotech company developing a novel approach to target inflammatory diseases based on the TREM-1 pathway. Its CEO, Dr Jean-Jacques Garaud explains why he decided to leave…
Anne-Laurence Sabatini, vice president of Cluster France, Canada & Benelux at LEO Pharma, discusses the transformation of the company and how this has trickled down to her cluster. Furthermore, she…
Phillipe Archinard CEO of Transgene shares insights on the latest technologies being developed by the gene therapy specialist, explains how France’s innovation landscape is improving, and highlights the current opportunities…
Olivier Laureau, global president of Servier Group, outlines the impact of recent acquisitions, the significance of Servier’s recently-opened commercial subsidiary in the US, the ongoing importance of France to the…
Stéphane Regnault, president of Vygon, shares how the company has grown in size and international footprint over the past several years as a leading domestic French medtech. Regnault goes on…
Brigitte Calles, newly appointed general manager of Ferring France discusses the important role the affiliate plays as a market leader in reproductive medicine & women’s health, gastroenterology and uro-oncology and…
Nicolas Chandellier, general manager of BD France, discusses the company’s historic positioning in France and how the organization has transformed to further act as a partner to the healthcare system…
Franck Cousserans, general manager of France and Belgium at Jazz Pharmaceuticals, highlights the company’s key products and the challenges of market access in France. Furthermore, he indicates the steps needed…
See our Cookie Privacy Policy Here
